Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum toxin for claw toe dystonia in Parkinson's disease
2008-007626-19Phase 4Active
- Sponsor
- Centre Hospitalier Universitaire de Clermont-Ferrand
- Start
- Mar 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of neuronox in Parkinson's disease (PD) (3 arms), sponsored by Centre Hospitalier Universitaire de Clermont-Ferrand. Primary endpoint: Clinical improvement after treatment. Started Mar 2009; status: active.
02
Drugs
neuronox
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2008-007626-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007626-19.